Let’s take Infectious Disease Testing to the Next Level

Microbial infections and antibiotic resistance can affect anybody, amounting to more than 15 Mio annual cases globally.

Ares Genetics and Curetis are part of the OpGen group.

Together we improve patient care and fight AMR through cutting edge molecular microbiology.

scroll down arrow

Microbial infections and antibiotic resistance can affect anybody, amounting to more than 15 Mio annual cases globally.

Decoding Infections

At Ares Genetics, we are working towards revolutionizing infectious disease diagnostics and therapeutics by artificial intelligence based DNA testing to improve patient outcomes at reduced costs.

Decoding Infections

At Ares Genetics, we are working towards revolutionizing infectious disease diagnostics and therapeutics by artificial intelligence based DNA testing to improve patient outcomes at reduced costs.

Our Vision

Conquering emerging antibiotic resistance, one of the biggest 21st century health threats and improving outcomes for patients with severe infections.

Our Mission

Revolutionizing infectious disease diagnostics and therapeutics by translating success stories from next-generation diagnostics and  precision medicine to microbial infections.

Vision & Mission

Leadership

Dr. Arne Materna

Managing Director & CEO

Dr. Arne Materna has been appointed Managing Director and CEO effective January 1, 2021. Arne brings a wealth of experience in the development and commercialization of leading-edge bioinformatics platforms and products in microbiology and NGS.

read more

Dr. Stephan Beisken

Director, Bioinformatics & Analytics

Dr. Stephan Beisken, Director of Bioinformatics & Analytics, joined from Discuva Limited, an antibiotic drug discovery company, where he was heading the Bioinformatics group.

read more

Dr. Johannes Weinberger

Director, NGS Laboratory

Dr. Johannes Weinberger, Director of NGS Laboratory, joined Ares Genetics from the Austrian Red Cross, where he served as co-Director of the Histocompatibility and Immunogenetics Lab and Principal Scientist at the R&D department.

read more

Faranak Atrzadeh

Head of Market Access USA

Faranak Atrzadeh, Head of Market Access USA, has over 20 years of experience in the IVD industry with emphasis in infectious diseases, point-of-care, and cancer diagnostics.

read more

Dr. Andreas E. Posch

Advisor

Dr. Andreas Posch, Special Advisor to Ares Genetics since January 2021, was Founding Managing Director & CEO of Ares Genetics from 2017 - 2020. Prior to building Ares Genetics together with Dr. Achim Plum, he developed Ares Genetics’ technology core and was responsible for Bioinformatics R&D at Siemens Healthcare.

read more

Dr. Achim Plum

Advisor

Dr. Achim Plum, Special Advisor to Ares Genetics since January 2021, was Founding Managing Director of Ares Genetics from 2017 - 2020.
Achim has more than 20 years of management experience in the diagnostics industry with a focus on innovative molecular diagnostics, biomarker development, and personalized medicine.

read more

Since its incorporation in March 2017, ARES has established an international team of highly committed business and technology experts with proven innovation & commercialization track-record.

Together, and supported by our global partner network, we are working towards revolutionizing infectious disease diagnostics and therapeutics.

Our Global Network

Commercial & Development Partners

OpGen-logocuretis-logoQIAGEN-logoSANDOZ-logoBGI-logoMGI-logomfpl-logoHIPS-logosaarland-university-logo

ARESdb Contributors

ARESdb builds on the GEnetic Antibiotic Resistance and Susceptibility Database (GEAR) and associated assets that the Curetis Group acquired from Siemens in late 2016.

Since its incorporation in March 2017, Ares Genetics has continuously expanded ARESdb with various development partners from academia and industry.

SIEMENS-Healthineers-logo

Supported by

FFG-logoWirschtaftsAgenturWien-logoWKO-logovienna-biocenter-logoeit-health-logoEU-logo
part of the OpGen group